The hottest FDA Approval Substack posts right now

Remdesivir, a controversial drug, was approved by the FDA for COVID treatment in kidney patients.
Family members of patients express anger and grief over the use of Remdesivir, linking it to worsened health conditions and deaths.
Financial incentives and hospital protocols played a significant role in the administration of Remdesivir, raising concerns about ethics and patient care.

There has been a resurgence of interest in the medical potential of psychedelics, with ongoing research and clinical trials exploring their efficacy in treating mental health conditions.
Despite the challenges and market fluctuations, there is increasing regulatory support for psychedelic drug trials, potentially leading to FDA approvals and breakthrough therapy designations for conditions like PTSD.
Psychedelic treatments involve controlled drug administration in conjunction with therapy, aiming to address the root causes of mental health disorders by stimulating new perspectives and thought patterns.

New FDA rules require medical device makers to meet specific cybersecurity criteria for approval.
Manufacturers must offer updates and patches for cybersecurity and develop a plan for addressing postmarket vulnerabilities.
Rules focus on devices connected to the internet, like insulin pumps and pacemakers, not legacy technology.

Cognitive Behavioral Therapy for Insomnia is the best first-line treatment for insomnia.
Sleep medications can help with treatment-resistant insomnia but come with significant negative side effects and should not be used long term.
Benadryl and doxylamine are common over-the-counter sleep aids with safety and efficacy concerns, potential for anticholinergic side effects and long-term safety issues.

Novartis' combination Tafinlar + Mekinist received FDA approval for pediatric patients with low-grade glioma
The spotlight is on Day One Biopharmaceuticals with the approval
The post is for paid subscribers only

Get a weekly roundup of the best Substack posts, by hacker news affinity:

Zepbound, a new weight loss drug, is approved by the FDA and competes with established drugs like Wegovy.
Zepbound may lead to a price war in the weight loss drug market, potentially resulting in lower prices for consumers.
Zepbound's unique combination of hormones helps with weight loss and Eli Lilly is already working on even more potent drugs in the future.

Karuna Therapeutics reported positive data on the third trial for schizophrenia.
The company is well-positioned to win FDA approval with a planned NDA by mid-2023.
The post is for paid subscribers only.